VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PFE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PFEPfizer Inc.
$29.39$167.5B
Overview & Tools
OverviewChart Terminal ↗AnalysisVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. PFE
  4. Financial Ratios

Pfizer Inc. (PFE) Financial Ratios

Latest Ratios: P/E Ratio 41.9x · EV/EBITDA 10.8x · ROE 8.9%. (1996–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

PFE Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$167.5B$141.6B$151.2B$164.4B$293.8B$337.1B$207.3B$210.8B$247.3B$208.0B$189.6B
Enterprise Value$233.8B$207.9B$217.2B$232.4B$328.2B$372.1B$243.8B$260.5B$287.9B$249.2B$228.1B
P/E Ratio →41.9118.3118.8277.569.3715.2222.6412.9522.189.7626.32
P/S Ratio2.632.262.382.762.904.154.985.156.063.963.59
P/B Ratio1.931.631.711.843.064.353.273.323.882.903.17
P/FCF14.2115.6015.3834.2911.2811.2817.8521.0918.1414.5913.64
P/OCF14.3112.1011.8718.8910.0410.3514.3916.7415.6312.6311.93

P/E links to full P/E history page with 30-year chart

PFE EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—3.323.413.903.244.585.856.377.054.744.32
EV / EBITDA10.798.669.8921.707.6014.6417.9219.9422.3612.2511.72
EV / EBIT13.4320.4019.5471.129.1314.5328.7320.2058.6418.3623.92
EV / FCF—22.9022.0848.4812.6112.4621.0026.0621.1217.4916.41

PFE Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin74.3%74.3%71.9%58.1%66.1%62.1%79.6%80.3%78.0%78.6%76.7%
Operating Margin27.8%27.8%23.5%7.4%37.7%24.9%21.2%17.9%16.5%26.8%26.0%
Net Profit Margin12.4%12.4%12.6%3.6%31.0%27.0%22.0%39.2%27.3%40.6%13.7%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE8.9%8.9%9.0%2.3%36.2%31.2%14.4%25.2%16.5%32.4%11.6%
ROA3.7%3.7%3.7%1.0%16.6%13.1%5.7%9.8%6.7%12.4%4.3%
ROIC8.5%8.5%7.2%2.3%23.5%14.3%6.2%5.0%4.6%10.0%10.4%
ROCE10.2%10.2%8.6%2.6%25.9%15.2%6.8%5.7%5.0%10.0%9.8%

PFE Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.780.780.760.790.360.480.600.800.650.590.69
Debt / EBITDA2.812.813.056.620.811.462.813.893.242.092.11
Net Debt / Equity—0.760.750.760.360.450.570.780.640.580.64
Net Debt / EBITDA2.762.763.006.350.801.382.683.813.152.031.98
Debt / FCF—7.306.7114.191.321.173.144.972.982.902.77
Interest Coverage3.823.823.601.4829.0519.835.868.203.7310.698.04

PFE Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.161.161.170.911.221.401.350.881.571.351.25
Quick Ratio0.870.870.920.691.001.191.040.691.331.101.03
Cash Ratio0.370.370.480.270.540.730.470.260.590.660.57
Asset Turnover—0.300.300.260.510.450.270.240.260.310.31
Inventory Turnover1.511.511.652.453.823.401.051.141.201.481.82
Days Sales Outstanding—92.3984.7795.2752.4170.7097.9584.84101.9178.2977.85

PFE Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield5.8%6.9%6.3%5.6%3.1%2.6%4.1%3.8%3.2%3.7%3.9%
Payout Ratio125.7%125.7%118.4%436.4%28.6%39.7%92.1%50.2%71.5%35.9%101.4%

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield2.4%5.5%5.3%1.3%10.7%6.6%4.4%7.7%4.5%10.2%3.8%
FCF Yield7.0%6.4%6.5%2.9%8.9%8.9%5.6%4.7%5.5%6.9%7.3%
Buyback Yield0.0%0.0%0.0%0.0%0.7%0.0%0.0%4.2%4.9%2.4%2.6%
Total Shareholder Yield5.8%6.9%6.3%5.6%3.7%2.6%4.1%8.0%8.2%6.1%6.5%
Shares Outstanding—$5.7B$5.7B$5.7B$5.7B$5.7B$5.6B$5.7B$6.0B$6.1B$6.2B

Key Metrics

Growth RegimeDecelerating
ProfitabilityModerate
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Patent cliff revenue erosion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Low Forward Multiples Reflect Patent Cliff Discount

Based on reported figures, PFE trades at 21.97x trailing P/E but only 10.11x forward P/E, a gap that suggests the market expects earnings to decline as roughly $17B–$18B of revenue faces loss of exclusivity.

The sharp compression from trailing to forward earnings multiples implies investors are discounting a meaningful earnings decline rather than valuing current profitability. Compared with peers such as MRK at 20.18x and AZN at 14.29x, PFE's forward multiple appears low, which may indicate a structural patent-cliff discount rather than a temporary mispricing. The 5.8% dividend yield is elevated versus the peer group, and investors should monitor whether earnings coverage remains adequate if forward estimates continue to fall.

Volatile Margins Obscure Underlying Earnings Power

As reported in quarterly filings, PFE's net margin swung from 25.3% in 2024Q3 to -9.4% in 2025Q4, while operating margin fell from 33.7% in 2025Q1 to 21.0% in 2025Q4, suggesting pronounced below-the-line volatility.

Operating margin compression alongside sharply negative net margins in some quarters suggests that non-recurring charges and other income items are materially distorting reported earnings. The gap between operating and net margin implies that headline profitability is a poor guide to recurring earnings power. Analysts may find a normalized operating margin, excluding restructuring and acquisition-related charges, more informative than reported net margin, though that adjustment cannot be verified from the supplied data alone.

Returns Stalled Near Single-Digit Levels

According to the reported ratio series, PFE's ROIC has hovered between 0.9% and 2.8% over the last ten quarters, with 2026Q3 at 1.8%, well below the 14.9%–41.8% range observed across most peers.

Persistently low ROIC relative to the peer group suggests the large goodwill base from recent acquisitions is absorbing capital without generating proportionate returns. The trend is flat rather than compounding, which may indicate that acquired intangibles have yet to translate into durable incremental profit. Investors should weigh whether returns can recover as the newer portfolio matures, or whether the current level reflects a structurally lower return profile.

Deleveraging Underway but Coverage Volatile

Based on reported figures, PFE's debt-to-equity ratio declined from 0.78 to 0.70 over the period, yet interest coverage swung between -1.31x and 7.02x, indicating uneven debt service capacity from quarter to quarter.

The gradual reduction in leverage suggests management is deleveraging, which is a constructive signal given the debt-funded acquisition strategy. However, the erratic interest coverage readings, including negative values in certain quarters, suggest that operating income is not consistently covering interest costs in every period. Investors should monitor whether coverage stabilizes as reported earnings normalize, as the current volatility warrants further investigation.

Peak Quarterly Margins May Not Persist

As reported, PFE's 2026Q3 free cash flow of $4.8B and 29.0% margin appear to have benefited from a $3.5B working capital inflow, suggesting the headline cash generation may overstate the durable base.

Relying on the most favorable quarter as a valuation anchor risks overstating sustainable cash generation, since working capital timing can reverse. The DSO and CCC readings show meaningful swings, which suggests collection and payables timing are driving a material share of reported cash flow. Investors may therefore wish to normalize free cash flow over several quarters before assessing dividend coverage and the true capacity to fund pipeline investment.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open PFE Terminal

PFE Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

PFE Stock Analysis

Bull/bear thesis, analyst target revisions, and earnings execution.

View Analysis

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

PFE — Frequently Asked Questions

Quick answers to the most common questions about buying PFE stock.

What is Pfizer Inc.'s P/E ratio?

Pfizer Inc.'s current P/E ratio is 41.9x. The historical average is 26.5x. This places it at the 83th percentile of its historical range.

What is Pfizer Inc.'s EV/EBITDA?

Pfizer Inc.'s current EV/EBITDA is 10.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 15.0x.

What is Pfizer Inc.'s ROE?

Pfizer Inc.'s return on equity (ROE) is 8.9%. The historical average is 20.2%.

Is PFE stock overvalued?

Based on historical data, Pfizer Inc. is trading at a P/E of 41.9x. This is at the 83th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What is Pfizer Inc.'s dividend yield?

Pfizer Inc.'s current dividend yield is 5.85% with a payout ratio of 125.7%.

What are Pfizer Inc.'s profit margins?

Pfizer Inc. has 74.3% gross margin and 27.8% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.

How much debt does Pfizer Inc. have?

Pfizer Inc.'s Debt/EBITDA ratio is 2.8x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.